Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech

Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.